US-based AMRI, which develops in-house pharmaceuticals in addition to providing contract services, has promoted Steven Hagen to vice president of pharmaceutical development and manufacturing.
In his new role Hagen will assume responsibility for AMRI's chemical development, small scale cGMP manufacturing and large scale commercial production.
He previously worked as vice president for quality and analytical chemistry at AMRI, where he was responsible for analytical chemistry, quality assurance and regulatory affairs at all the company’s locations.
Prior to joining AMRI in 2005 Hagen spent over 10 years at Pfizer in various roles, culminating in director of analytical research and development at the company’s global research and development division.
Hagen replaces Jonathan Evans who has left to pursue another career opportunity.
AMRI has also promoted Luckner Ulysse to vice president, chemical development. Ulysse will manage the company's small scale cGMP and chemical development operations in New York and integrate with AMRI’s overseas facilities.
Prior to joining AMRI in 1999, Ulysse was senior research chemist at Advanced ChemTech.
Halozyme Therapeutics has shaken up its management team with the appointments of Michael LaBarre as vice president, product development and Patrick O’Connor as vice president, research.
LaBarre will utilise his knowledge of chemistry, manufacturing and controls (CMC) to assist with Halozyme’s product development. This experience covers both biologics and small molecules.
Before joining Halozyme LaBarre held the post of vice president of product development at Paramount BioSciences.
In this capacity LaBarre led CMC efforts for all of the product development programs within Paramount’s portfolio. He has also worked at Biogen Idec, Vical and Hybritech.
O’Connor is joining Halozyme from Ardea Biosciences where he was senior vice president and chief scientific officer. In his new role at Halozyme O’Conner will provide leadership to the company’s various research programmes.
Prior to working at Ardea O’Connor held various positions at Pfizer, culminating in the post of vice president, research therapeutic area head, global oncology.
Cadence Pharmaceuticals has appointed Malcolm Lloyd-Smith to the position of senior vice president, regulatory affairs and quality assurance. He replaces Malvina Laudicina, who resigned from the company for medical reasons.
Lloyd-Smith will assist in achieving regulatory objectives for Cadence’s two Phase III product candidates. He has previously worked at Elan Pharmaceuticals and Bristol-Myers Squibb.